During 2018 Q3 the big money sentiment increased to 1.71. That’s change of 0.49, from 2018Q2’s 1.22. 9 investors sold all, 8 reduced holdings as AcelRx Pharmaceuticals, Inc. ratio increased. 17 increased positions while 12 funds acquired positions. Funds hold 6.40 million shares thus 42.63% more from 2018Q2’s 4.49 million shares.
Moreover, Comml Bank Of Mellon Corp has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 43,283 shs. Moreover, Goldman Sachs Grp Inc Inc has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Virtu Financial Lc owns 34,770 shs. Gsa Cap Ltd Liability Partnership has 120,158 shs for 0.03% of their capital. Bluecrest Cap Limited has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Fmr Limited Liability Company invested in 226,844 shs. Vanguard Group Incorporated stated it has 2.09 million shs or 0% of all its holdings. Fosun Intl owns 479,048 shs. Cornerstone Cap stated it has 40,000 shs or 0.02% of all its holdings. Moreover, Renaissance Technologies Ltd Liability Com has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 428,700 shs. Blackrock Inc stated it has 786,034 shs. Raymond James And Assoc invested in 0% or 15,000 shs. Citadel Limited Liability Com has invested 0% of its capital in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Art Limited Liability Company reported 35,198 shs. Zpr Inv accumulated 11,299 shs or 0.07% of the stock.

AcelRx Pharmaceuticals, Inc. had 3 selling transactions and 6 buys since September 24, 2018. This’s net activity of $22,185. Angotti Vincent J. bought $10,024 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) on Friday, December 14. 5,216 shs valued at $26,080 were sold by Hamel Lawrence G on Monday, October 15. EDWARDS MARK G bought $58,376 worth of stock or 20,700 shs. $141,755 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) shs were sold by Dasu Badri N. On Monday, November 19 16,000 shs were bought by Palmer Pamela P, worth $49,120.

On March, 14. Investors wait AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) to reveal its quarterly earnings, according to Faxor. Analysts forecast 0.00 % diference or $-0.20 from the $-0.2 EPS from 2018. Analysts at Wall Street see AcelRx Pharmaceuticals, Inc.’s -4.76 % EPS growth compared to $-0.21 EPS for last quarter. ACRX touched $3.66 during the last trading session after $0.3 change.AcelRx Pharmaceuticals, Inc. has 3.95M shares volume, 98.36% up from normal. ACRX is uptrending and has moved 48.44% since March 3, 2018. ACRX outperformed by 48.44% the S&P 500.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Ratings Coverage

In total 4 analysts cover AcelRx Pharmaceuticals (NASDAQ:ACRX). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 5 are the (NASDAQ:ACRX)’s analyst reports since October 10, 2018 according to StockzIntelligence Inc. The company rating was upgraded by Jefferies on Monday, October 15. On Wednesday, October 10 Ladenburg Thalmann maintained the shares of ACRX in report with “Buy” rating.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.The firm is worth $279.60 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain.Currently it has negative earnings. The company's late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

For more AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) news announced briefly go to: Seekingalpha.com, Seekingalpha.com, Benzinga.com, Benzinga.com or Benzinga.com. The titles are as follows: “Your Daily Pharma Scoop: AcelRx, How Far Can It Go; Trevena’s Future – Seeking Alpha” announced on October 15, 2018, “AcelRx Finally Has An AdCom Date. Time For A Run Up? – Seeking Alpha” on September 13, 2018, “31 Stocks Moving In Friday’s Pre-Market Session – Benzinga” with a publish date: February 15, 2019, “Analyst: AcelRx (NASDAQ:ACRX) Will Address FDA Concerns, Secure Approval This Year – Benzinga” and the last “71 Biggest Movers From Yesterday – Benzinga” with publication date: February 20, 2019.